The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study
Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary i...
Gespeichert in:
| Veröffentlicht in: | Frontiers in medicine Jg. 8; S. 743180 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Switzerland
Frontiers Media SA
16.12.2021
Frontiers Media S.A |
| Schlagworte: | |
| ISSN: | 2296-858X, 2296-858X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background:
Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary in order to evaluate the effects of past health care policies and to orient and inform new national and international healthcare strategies.
Methods:
Data were extracted from the GBD 2019 study, which collates a systematic review of relevant scientific literature, national surveys, claims data, and primary care sources on the prevalence of psoriasis. Prevalence data were combined with disability weight (DW) to yield years lived with disability (YLDs). Measures of burden at global, regional, and national levels were generated for incidence, prevalence, and YLDs, due to psoriatic disease. All measures were reported as absolute numbers, percentages, and crude and age-adjusted rates per 100,000 persons. In addition, psoriasis burden was assessed by socio-demographic index (SDI).
Findings:
According to the GBD 2019 methodology, there were 4,622,594 (95% uncertainty interval or UI 4,458,904–4,780,771) incident cases of psoriasis worldwide in 2019. The age-standardized incidence rate in 2019 was 57.8 (95% UI 55.8–59.7) per 100,000 people. With respect to 1990, this corresponded to a decrease of 20.0% (95% UI −20.2 to −19.8). By sex, the age-standardized incidence rate was similar between men [57.8 (95% UI 55.8–59.8) per 100,000 people] and women [(57.8 (95% UI 55.8–59.7) per 100,000 people]. With respect to 1990, this corresponded to a decrease by 19.5% (95% UI −19.8 to −19.2) and by 20.4% (95% UI −20.7 to −20.2) for men and women, respectively. The age-standardized incidence rate per 100,000 persons was found to vary widely across geographic locations. Regionally, high-income countries and territories had the highest age-standardized incidence rate of psoriasis [112.6 (95% UI 108.9–116.1)], followed by high-middle SDI countries [69.4 (95% UI 67.1–71.9)], while low SDI countries reported the lowest rate [38.1 (95% UI 36.8–39.5)]. Similar trends were detected for prevalence and YLDs.
Conclusion:
In general, psoriasis burden is greatest in the age group of 60–69 years, with a relatively similar burden among men and women. The burden is disproportionately greater in high-income and high SDI index countries of North America and Europe. With advances in psoriasis therapeutics, objective evaluation of psoriasis disease burden is critical to track the progress at the population level. |
|---|---|
| AbstractList | Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary in order to evaluate the effects of past health care policies and to orient and inform new national and international healthcare strategies. Methods: Data were extracted from the GBD 2019 study, which collates a systematic review of relevant scientific literature, national surveys, claims data, and primary care sources on the prevalence of psoriasis. Prevalence data were combined with disability weight (DW) to yield years lived with disability (YLDs). Measures of burden at global, regional, and national levels were generated for incidence, prevalence, and YLDs, due to psoriatic disease. All measures were reported as absolute numbers, percentages, and crude and age-adjusted rates per 100,000 persons. In addition, psoriasis burden was assessed by socio-demographic index (SDI). Findings: According to the GBD 2019 methodology, there were 4,622,594 (95% uncertainty interval or UI 4,458,904–4,780,771) incident cases of psoriasis worldwide in 2019. The age-standardized incidence rate in 2019 was 57.8 (95% UI 55.8–59.7) per 100,000 people. With respect to 1990, this corresponded to a decrease of 20.0% (95% UI −20.2 to −19.8). By sex, the age-standardized incidence rate was similar between men [57.8 (95% UI 55.8–59.8) per 100,000 people] and women [(57.8 (95% UI 55.8–59.7) per 100,000 people]. With respect to 1990, this corresponded to a decrease by 19.5% (95% UI −19.8 to −19.2) and by 20.4% (95% UI −20.7 to −20.2) for men and women, respectively. The age-standardized incidence rate per 100,000 persons was found to vary widely across geographic locations. Regionally, high-income countries and territories had the highest age-standardized incidence rate of psoriasis [112.6 (95% UI 108.9–116.1)], followed by high-middle SDI countries [69.4 (95% UI 67.1–71.9)], while low SDI countries reported the lowest rate [38.1 (95% UI 36.8–39.5)]. Similar trends were detected for prevalence and YLDs. Conclusion: In general, psoriasis burden is greatest in the age group of 60–69 years, with a relatively similar burden among men and women. The burden is disproportionately greater in high-income and high SDI index countries of North America and Europe. With advances in psoriasis therapeutics, objective evaluation of psoriasis disease burden is critical to track the progress at the population level. Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary in order to evaluate the effects of past health care policies and to orient and inform new national and international healthcare strategies. Methods: Data were extracted from the GBD 2019 study, which collates a systematic review of relevant scientific literature, national surveys, claims data, and primary care sources on the prevalence of psoriasis. Prevalence data were combined with disability weight (DW) to yield years lived with disability (YLDs). Measures of burden at global, regional, and national levels were generated for incidence, prevalence, and YLDs, due to psoriatic disease. All measures were reported as absolute numbers, percentages, and crude and age-adjusted rates per 100,000 persons. In addition, psoriasis burden was assessed by socio-demographic index (SDI). Findings: According to the GBD 2019 methodology, there were 4,622,594 (95% uncertainty interval or UI 4,458,904–4,780,771) incident cases of psoriasis worldwide in 2019. The age-standardized incidence rate in 2019 was 57.8 (95% UI 55.8–59.7) per 100,000 people. With respect to 1990, this corresponded to a decrease of 20.0% (95% UI −20.2 to −19.8). By sex, the age-standardized incidence rate was similar between men [57.8 (95% UI 55.8–59.8) per 100,000 people] and women [(57.8 (95% UI 55.8–59.7) per 100,000 people]. With respect to 1990, this corresponded to a decrease by 19.5% (95% UI −19.8 to −19.2) and by 20.4% (95% UI −20.7 to −20.2) for men and women, respectively. The age-standardized incidence rate per 100,000 persons was found to vary widely across geographic locations. Regionally, high-income countries and territories had the highest age-standardized incidence rate of psoriasis [112.6 (95% UI 108.9–116.1)], followed by high-middle SDI countries [69.4 (95% UI 67.1–71.9)], while low SDI countries reported the lowest rate [38.1 (95% UI 36.8–39.5)]. Similar trends were detected for prevalence and YLDs. Conclusion: In general, psoriasis burden is greatest in the age group of 60–69 years, with a relatively similar burden among men and women. The burden is disproportionately greater in high-income and high SDI index countries of North America and Europe. With advances in psoriasis therapeutics, objective evaluation of psoriasis disease burden is critical to track the progress at the population level. Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary in order to evaluate the effects of past health care policies and to orient and inform new national and international healthcare strategies. Data were extracted from the GBD 2019 study, which collates a systematic review of relevant scientific literature, national surveys, claims data, and primary care sources on the prevalence of psoriasis. Prevalence data were combined with disability weight (DW) to yield years lived with disability (YLDs). Measures of burden at global, regional, and national levels were generated for incidence, prevalence, and YLDs, due to psoriatic disease. All measures were reported as absolute numbers, percentages, and crude and age-adjusted rates per 100,000 persons. In addition, psoriasis burden was assessed by socio-demographic index (SDI). According to the GBD 2019 methodology, there were 4,622,594 (95% uncertainty interval or UI 4,458,904-4,780,771) incident cases of psoriasis worldwide in 2019. The age-standardized incidence rate in 2019 was 57.8 (95% UI 55.8-59.7) per 100,000 people. With respect to 1990, this corresponded to a decrease of 20.0% (95% UI -20.2 to -19.8). By sex, the age-standardized incidence rate was similar between men [57.8 (95% UI 55.8-59.8) per 100,000 people] and women [(57.8 (95% UI 55.8-59.7) per 100,000 people]. With respect to 1990, this corresponded to a decrease by 19.5% (95% UI -19.8 to -19.2) and by 20.4% (95% UI -20.7 to -20.2) for men and women, respectively. The age-standardized incidence rate per 100,000 persons was found to vary widely across geographic locations. Regionally, high-income countries and territories had the highest age-standardized incidence rate of psoriasis [112.6 (95% UI 108.9-116.1)], followed by high-middle SDI countries [69.4 (95% UI 67.1-71.9)], while low SDI countries reported the lowest rate [38.1 (95% UI 36.8-39.5)]. Similar trends were detected for prevalence and YLDs. In general, psoriasis burden is greatest in the age group of 60-69 years, with a relatively similar burden among men and women. The burden is disproportionately greater in high-income and high SDI index countries of North America and Europe. With advances in psoriasis therapeutics, objective evaluation of psoriasis disease burden is critical to track the progress at the population level. Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary in order to evaluate the effects of past health care policies and to orient and inform new national and international healthcare strategies. Methods: Data were extracted from the GBD 2019 study, which collates a systematic review of relevant scientific literature, national surveys, claims data, and primary care sources on the prevalence of psoriasis. Prevalence data were combined with disability weight (DW) to yield years lived with disability (YLDs). Measures of burden at global, regional, and national levels were generated for incidence, prevalence, and YLDs, due to psoriatic disease. All measures were reported as absolute numbers, percentages, and crude and age-adjusted rates per 100,000 persons. In addition, psoriasis burden was assessed by socio-demographic index (SDI). Findings: According to the GBD 2019 methodology, there were 4,622,594 (95% uncertainty interval or UI 4,458,904-4,780,771) incident cases of psoriasis worldwide in 2019. The age-standardized incidence rate in 2019 was 57.8 (95% UI 55.8-59.7) per 100,000 people. With respect to 1990, this corresponded to a decrease of 20.0% (95% UI -20.2 to -19.8). By sex, the age-standardized incidence rate was similar between men [57.8 (95% UI 55.8-59.8) per 100,000 people] and women [(57.8 (95% UI 55.8-59.7) per 100,000 people]. With respect to 1990, this corresponded to a decrease by 19.5% (95% UI -19.8 to -19.2) and by 20.4% (95% UI -20.7 to -20.2) for men and women, respectively. The age-standardized incidence rate per 100,000 persons was found to vary widely across geographic locations. Regionally, high-income countries and territories had the highest age-standardized incidence rate of psoriasis [112.6 (95% UI 108.9-116.1)], followed by high-middle SDI countries [69.4 (95% UI 67.1-71.9)], while low SDI countries reported the lowest rate [38.1 (95% UI 36.8-39.5)]. Similar trends were detected for prevalence and YLDs. Conclusion: In general, psoriasis burden is greatest in the age group of 60-69 years, with a relatively similar burden among men and women. The burden is disproportionately greater in high-income and high SDI index countries of North America and Europe. With advances in psoriasis therapeutics, objective evaluation of psoriasis disease burden is critical to track the progress at the population level.Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have transformed the therapeutic landscape, updated estimates of the Global Burden of Disease (GBD) imposed by psoriasis are necessary in order to evaluate the effects of past health care policies and to orient and inform new national and international healthcare strategies. Methods: Data were extracted from the GBD 2019 study, which collates a systematic review of relevant scientific literature, national surveys, claims data, and primary care sources on the prevalence of psoriasis. Prevalence data were combined with disability weight (DW) to yield years lived with disability (YLDs). Measures of burden at global, regional, and national levels were generated for incidence, prevalence, and YLDs, due to psoriatic disease. All measures were reported as absolute numbers, percentages, and crude and age-adjusted rates per 100,000 persons. In addition, psoriasis burden was assessed by socio-demographic index (SDI). Findings: According to the GBD 2019 methodology, there were 4,622,594 (95% uncertainty interval or UI 4,458,904-4,780,771) incident cases of psoriasis worldwide in 2019. The age-standardized incidence rate in 2019 was 57.8 (95% UI 55.8-59.7) per 100,000 people. With respect to 1990, this corresponded to a decrease of 20.0% (95% UI -20.2 to -19.8). By sex, the age-standardized incidence rate was similar between men [57.8 (95% UI 55.8-59.8) per 100,000 people] and women [(57.8 (95% UI 55.8-59.7) per 100,000 people]. With respect to 1990, this corresponded to a decrease by 19.5% (95% UI -19.8 to -19.2) and by 20.4% (95% UI -20.7 to -20.2) for men and women, respectively. The age-standardized incidence rate per 100,000 persons was found to vary widely across geographic locations. Regionally, high-income countries and territories had the highest age-standardized incidence rate of psoriasis [112.6 (95% UI 108.9-116.1)], followed by high-middle SDI countries [69.4 (95% UI 67.1-71.9)], while low SDI countries reported the lowest rate [38.1 (95% UI 36.8-39.5)]. Similar trends were detected for prevalence and YLDs. Conclusion: In general, psoriasis burden is greatest in the age group of 60-69 years, with a relatively similar burden among men and women. The burden is disproportionately greater in high-income and high SDI index countries of North America and Europe. With advances in psoriasis therapeutics, objective evaluation of psoriasis disease burden is critical to track the progress at the population level. |
| Author | Bragazzi, Nicola Luigi La Vecchia, Carlo Karimkhani Aksut, Chante McGonagle, Dennis Grada, Ayman Naghavi, Mohsen Guo, Cui Tam, Lai-Shan Wu, Dongze Dellavalle, Robert Alicandro, Gianfranco Cooper, Kevin D. Damiani, Giovanni Wong, Priscilla |
| AuthorAffiliation | 2 Clinical Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Ortopedico Galeazzi , Milan , Italy 3 Department of Biomedical, Surgical and Dental Sciences, University of Milan , Milan , Italy 8 National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Chapel Allerton Hospital, University of Leeds , Leeds , United Kingdom 11 Institute for Health Metrics and Evaluation, University of Washington , Seattle, WA , United States 1 Department of Dermatology, Case Western Reserve University , Cleveland, OH , United States 5 Department of Dermatology, University of Anschutz Medical Campus , Aurora, CO , United States 7 Department of Clinical Sciences and Community Health, Università degli Studi di Milano , Milan , Italy 4 Chapel Allerton Hospital, University of Leeds , Leeds , United Kingdom 9 Jockey Club School of Public Health and Primary Care, The Chinese Unive |
| AuthorAffiliation_xml | – name: 8 National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, Chapel Allerton Hospital, University of Leeds , Leeds , United Kingdom – name: 7 Department of Clinical Sciences and Community Health, Università degli Studi di Milano , Milan , Italy – name: 11 Institute for Health Metrics and Evaluation, University of Washington , Seattle, WA , United States – name: 9 Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin , Hong Kong SAR , China – name: 10 Department of Dermatology, Boston University School of Medicine , Boston, MA , United States – name: 2 Clinical Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Ortopedico Galeazzi , Milan , Italy – name: 1 Department of Dermatology, Case Western Reserve University , Cleveland, OH , United States – name: 5 Department of Dermatology, University of Anschutz Medical Campus , Aurora, CO , United States – name: 3 Department of Biomedical, Surgical and Dental Sciences, University of Milan , Milan , Italy – name: 4 Chapel Allerton Hospital, University of Leeds , Leeds , United Kingdom – name: 6 Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin , Hong Kong SAR , China |
| Author_xml | – sequence: 1 givenname: Giovanni surname: Damiani fullname: Damiani, Giovanni – sequence: 2 givenname: Nicola Luigi surname: Bragazzi fullname: Bragazzi, Nicola Luigi – sequence: 3 givenname: Chante surname: Karimkhani Aksut fullname: Karimkhani Aksut, Chante – sequence: 4 givenname: Dongze surname: Wu fullname: Wu, Dongze – sequence: 5 givenname: Gianfranco surname: Alicandro fullname: Alicandro, Gianfranco – sequence: 6 givenname: Dennis surname: McGonagle fullname: McGonagle, Dennis – sequence: 7 givenname: Cui surname: Guo fullname: Guo, Cui – sequence: 8 givenname: Robert surname: Dellavalle fullname: Dellavalle, Robert – sequence: 9 givenname: Ayman surname: Grada fullname: Grada, Ayman – sequence: 10 givenname: Priscilla surname: Wong fullname: Wong, Priscilla – sequence: 11 givenname: Carlo surname: La Vecchia fullname: La Vecchia, Carlo – sequence: 12 givenname: Lai-Shan surname: Tam fullname: Tam, Lai-Shan – sequence: 13 givenname: Kevin D. surname: Cooper fullname: Cooper, Kevin D. – sequence: 14 givenname: Mohsen surname: Naghavi fullname: Naghavi, Mohsen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34977058$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kstvEzEQxi1UREvpnRNaiQuHJvj94IBECy2RKkBQJG6W14_E0WZd7F2k_Pc4SYnSSpw8Y__m04znew6O-tR7AF4iOCVEqrdh5d0UQ4ymghIk4RNwgrHiE8nkr6OD-BiclbKEECKCGUXkGTgmVAkBmTwB69uFb6671JruvPnu5zH1m8j0rvlihm3WXIzZ-b5JoflWUo6mxPKusmXshrIlZ32J80VNrnJaNcNe8aDyYyzeFN9giFTzYxjd-gV4GkxX_Nn9eQp-Xn26vfw8ufl6Pbv8cDOxjPFhIpjx0rSSSOlaD70SjEGFLYZUUsGNgaoNErbSMkUExQp64ig1RobgBLXkFMx2ui6Zpb7LcWXyWicT9fYi5bk2eYi289oTSDB3kgUeqIVIOsyYckKF1hrlSNV6v9O6G9v6-9b3QzbdA9GHL31c6Hn6o6VAnElWBd7cC-T0e_Rl0KtYrO860_s0Fo054nUEzmlFXz9Cl2nMdR9FEywwF0pBWKlXhx3tW_m34QrAHWBzKiX7sEcQ1Bsf6Y2P9MZHeuejWsIfldg4bM1QZ4rd_wv_AhO3y7o |
| CitedBy_id | crossref_primary_10_1111_dth_15598 crossref_primary_10_1111_jdv_20863 crossref_primary_10_1002_bab_2619 crossref_primary_10_1038_s41598_025_86779_1 crossref_primary_10_1080_17512433_2023_2219054 crossref_primary_10_3390_medicina58101443 crossref_primary_10_3389_fimmu_2022_849560 crossref_primary_10_3390_ijms25147745 crossref_primary_10_1007_s43440_025_00710_z crossref_primary_10_3390_ijms23158575 crossref_primary_10_1007_s40264_024_01427_3 crossref_primary_10_3390_nu14204324 crossref_primary_10_1007_s13555_025_01353_x crossref_primary_10_1016_j_retram_2025_103504 crossref_primary_10_3390_ijms26104798 crossref_primary_10_3389_fmed_2024_1455953 crossref_primary_10_1016_j_intimp_2022_109341 crossref_primary_10_1155_2022_8802469 crossref_primary_10_3390_ijms25073617 crossref_primary_10_1111_ijd_17292 crossref_primary_10_1016_j_clindermatol_2025_01_001 crossref_primary_10_1007_s13555_024_01274_1 crossref_primary_10_1038_s41419_025_07357_x crossref_primary_10_1016_j_indcrop_2025_121575 crossref_primary_10_5826_dpc_1502a4976 crossref_primary_10_1016_j_jddst_2024_106275 crossref_primary_10_3390_pathogens14090956 crossref_primary_10_2147_JIR_S468746 crossref_primary_10_3389_fgene_2024_1365273 crossref_primary_10_1080_14712598_2024_2325547 crossref_primary_10_3390_pharmaceutics16010111 crossref_primary_10_1007_s40267_023_01025_w crossref_primary_10_1001_jamadermatol_2022_3682 crossref_primary_10_1093_rheumatology_kead462 crossref_primary_10_3389_fimmu_2025_1573495 crossref_primary_10_1159_000531420 crossref_primary_10_1038_s41598_024_59603_5 crossref_primary_10_1002_jvc2_70134 crossref_primary_10_1016_j_intimp_2025_114896 crossref_primary_10_1080_03007995_2023_2288280 crossref_primary_10_7759_cureus_74252 crossref_primary_10_1093_bjd_ljad035 crossref_primary_10_4103_ds_DS_D_22_00096 crossref_primary_10_1080_14712598_2025_2538608 crossref_primary_10_3389_fpubh_2023_1225931 crossref_primary_10_3389_fimmu_2024_1410540 crossref_primary_10_7759_cureus_82782 crossref_primary_10_1111_jdv_20786 crossref_primary_10_1016_j_intimp_2023_110024 crossref_primary_10_1007_s13555_024_01211_2 crossref_primary_10_3390_biomedicines12010249 crossref_primary_10_1016_j_ejpb_2024_114523 crossref_primary_10_1007_s13555_024_01159_3 crossref_primary_10_1111_ajd_14021 crossref_primary_10_1007_s12275_024_00167_4 crossref_primary_10_2147_PTT_S526748 crossref_primary_10_3390_ijms26115005 crossref_primary_10_7759_cureus_50588 crossref_primary_10_3390_antiox11071269 crossref_primary_10_3390_antiox14010027 crossref_primary_10_3390_ijerph19148345 crossref_primary_10_3390_nutraceuticals5030024 crossref_primary_10_3390_jpm12060924 crossref_primary_10_1002_jvc2_324 crossref_primary_10_32352_0367_3057_6_24_05 crossref_primary_10_1111_1346_8138_17695 crossref_primary_10_3390_ijms24129850 crossref_primary_10_1111_ajd_14154 crossref_primary_10_3390_ijms24076061 crossref_primary_10_1093_ced_llaf050 crossref_primary_10_1080_17512433_2023_2259300 crossref_primary_10_1097_CM9_0000000000003771 crossref_primary_10_3390_gels10020119 crossref_primary_10_3892_etm_2025_12925 crossref_primary_10_54393_pjhs_v6i7_1826 crossref_primary_10_3390_ijms23010121 crossref_primary_10_1016_j_ejphar_2024_177083 crossref_primary_10_1159_000538805 crossref_primary_10_2340_actadv_v104_20329 crossref_primary_10_3389_fmed_2023_1203426 crossref_primary_10_1038_s41598_024_77222_y crossref_primary_10_7759_cureus_73929 crossref_primary_10_3390_ijms26178520 crossref_primary_10_1155_2024_6530352 crossref_primary_10_1080_08820139_2024_2302823 crossref_primary_10_1111_jdv_18572 crossref_primary_10_1038_s41598_025_90961_w crossref_primary_10_1016_j_jddst_2024_106521 crossref_primary_10_1080_14712598_2022_2070428 crossref_primary_10_1080_14737167_2022_2063842 crossref_primary_10_1111_jdv_20198 crossref_primary_10_1007_s00403_024_03191_x crossref_primary_10_1111_ijd_70053 crossref_primary_10_1016_j_bbrc_2022_07_041 crossref_primary_10_1080_17435889_2024_2405455 crossref_primary_10_1016_j_jconrel_2025_114218 crossref_primary_10_3390_healthcare11131849 crossref_primary_10_1016_j_lfs_2025_123698 crossref_primary_10_1515_biol_2025_1139 crossref_primary_10_7759_cureus_61567 crossref_primary_10_1007_s13555_022_00687_0 crossref_primary_10_3390_biomedicines10081976 crossref_primary_10_18203_2320_6012_ijrms20252435 crossref_primary_10_1016_j_biopha_2025_118349 crossref_primary_10_1007_s00210_025_04334_1 crossref_primary_10_1177_10600280231153863 crossref_primary_10_3390_healthcare10112323 crossref_primary_10_1016_j_ad_2024_10_005 crossref_primary_10_1159_000541951 crossref_primary_10_1007_s40257_024_00854_3 crossref_primary_10_2340_actadv_v104_12430 crossref_primary_10_1016_j_lfs_2024_122991 crossref_primary_10_1007_s10616_023_00574_2 crossref_primary_10_1038_s41392_023_01655_6 crossref_primary_10_2147_CCID_S467442 crossref_primary_10_1016_j_biopha_2025_117922 crossref_primary_10_3389_fmed_2022_875492 crossref_primary_10_1007_s12016_025_09089_4 crossref_primary_10_1080_03007995_2023_2260304 crossref_primary_10_1111_exd_14906 crossref_primary_10_3390_ijms252313229 crossref_primary_10_1111_dth_15772 crossref_primary_10_2147_CCID_S435624 crossref_primary_10_1007_s13555_024_01210_3 crossref_primary_10_1016_j_intimp_2024_112225 crossref_primary_10_3390_vaccines10050646 crossref_primary_10_1007_s13555_025_01428_9 crossref_primary_10_1007_s13204_025_03101_1 crossref_primary_10_1177_24755303241302070 crossref_primary_10_1111_ijd_17005 crossref_primary_10_12731_2658_6649_2025_17_1_1164 crossref_primary_10_1016_j_ad_2024_06_008 crossref_primary_10_1159_000543351 crossref_primary_10_1111_exd_70054 crossref_primary_10_1007_s13555_025_01515_x crossref_primary_10_2217_bmm_2023_0425 crossref_primary_10_3390_jpm14060605 crossref_primary_10_1155_2022_5978271 crossref_primary_10_1080_14737167_2023_2190514 crossref_primary_10_33393_grhta_2022_2474 crossref_primary_10_1016_j_jconrel_2024_09_032 crossref_primary_10_1002_hsr2_71128 crossref_primary_10_1097_BOR_0000000000001085 crossref_primary_10_2147_PTT_S532112 crossref_primary_10_1371_journal_pone_0289794 crossref_primary_10_1021_acs_jmedchem_5c01060 crossref_primary_10_3390_ph16040617 crossref_primary_10_1186_s12951_022_01651_y crossref_primary_10_1186_s12902_025_01996_z crossref_primary_10_1186_s13690_024_01332_2 crossref_primary_10_1016_j_jaim_2024_101091 crossref_primary_10_1080_20415990_2024_2343646 crossref_primary_10_3390_ijms25115705 crossref_primary_10_3390_medicina61030397 crossref_primary_10_1186_s12865_025_00724_5 crossref_primary_10_1080_03007995_2022_2129803 crossref_primary_10_1016_j_phanu_2024_100416 crossref_primary_10_1007_s12013_024_01620_2 crossref_primary_10_3389_fmed_2025_1605100 crossref_primary_10_3389_fimmu_2024_1360618 crossref_primary_10_3390_diagnostics14242887 crossref_primary_10_1186_s12888_025_06687_6 crossref_primary_10_3390_ijms26115082 crossref_primary_10_1111_dth_15687 crossref_primary_10_3390_antiox13101222 crossref_primary_10_3390_ijerph19148723 crossref_primary_10_7759_cureus_63379 crossref_primary_10_1111_jocd_16140 crossref_primary_10_13005_bbra_3237 crossref_primary_10_2147_CCID_S430621 crossref_primary_10_3390_life15040627 crossref_primary_10_2147_CCID_S374556 crossref_primary_10_1186_s41065_025_00421_8 crossref_primary_10_1093_ced_llae240 crossref_primary_10_3389_fimmu_2023_1255909 crossref_primary_10_2147_CCID_S473237 crossref_primary_10_1016_j_jddst_2024_105738 crossref_primary_10_33590_dermatolamj_WRTV2812 crossref_primary_10_3390_nu17091473 crossref_primary_10_7759_cureus_52139 crossref_primary_10_1007_s00403_024_02823_6 crossref_primary_10_1080_03007995_2022_2078099 crossref_primary_10_7759_cureus_88464 crossref_primary_10_1111_ijd_17848 crossref_primary_10_3389_fpubh_2025_1518681 crossref_primary_10_1080_03007995_2023_2214046 crossref_primary_10_2340_actadv_v105_42840 crossref_primary_10_2147_CCID_S378143 crossref_primary_10_3390_biomedicines11041036 crossref_primary_10_1088_1748_605X_ad5e51 crossref_primary_10_1007_s13555_023_00986_0 crossref_primary_10_3389_fimmu_2022_847312 crossref_primary_10_1002_clc_70047 crossref_primary_10_3390_antib13030076 crossref_primary_10_1007_s00403_025_03808_9 crossref_primary_10_5692_clinicalneurol_cn_002027 crossref_primary_10_32345_2664_4738_1_2025_11 crossref_primary_10_1002_advs_202417093 crossref_primary_10_2147_CCID_S356801 crossref_primary_10_1111_ijd_17958 crossref_primary_10_1007_s13555_023_00987_z crossref_primary_10_1007_s13555_024_01228_7 crossref_primary_10_1080_14728222_2024_2375373 crossref_primary_10_1371_journal_pone_0312603 crossref_primary_10_1093_ced_llad168 crossref_primary_10_1016_j_ijcard_2024_131819 crossref_primary_10_25208_vdv16877 crossref_primary_10_1080_1744666X_2023_2219897 crossref_primary_10_1007_s13555_023_01041_8 crossref_primary_10_3390_biomedicines10102387 crossref_primary_10_1159_000529398 crossref_primary_10_3390_ijms242316898 |
| Cites_doi | 10.1136/bmj.m1590 10.1007/s00296-013-2876-z 10.1007/s10875-017-0464-9 10.1016/S0140-6736(16)30388-9 10.1038/nrrheum.2017.188 10.1016/S0140-6736(12)61690-0 10.5114/aoms.2018.74021 10.1159/000450826 10.1038/nrdp.2016.82 10.1038/s41584-018-0147-9 10.1001/jamadermatol.2016.5538 10.2147/PTT.S126281 10.1016/S0140-6736(17)32130-X 10.1016/S0140-6736(20)30925-9 10.1016/j.jaad.2020.04.139 10.1016/j.semarthrit.2017.05.010 10.1016/S0140-6736(12)61899-6 10.1111/jdv.14460 10.1016/S0140-6736(18)32279-7 10.1111/ijd.14864 10.1016/j.jaad.2018.12.037 10.1038/jid.2012.339 10.1136/annrheumdis-2018-214065 10.1038/ncomms6621 10.1002/art.40830 10.1016/S0140-6736(18)32281-5 10.1016/j.jaad.2017.10.012 10.1007/s40257-017-0332-7 10.1001/jamadermatol.2013.5015 10.1016/S0140-6736(15)61340-X 10.1111/ajd.13710 10.1136/annrheumdis-2012-201706 10.1111/j.1365-2133.2009.09505.x 10.1016/S0140-6736(16)31467-2 10.46234/ccdcw2021.123 10.1136/bmjopen-2018-028116 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Damiani, Bragazzi, Karimkhani Aksut, Wu, Alicandro, McGonagle, Guo, Dellavalle, Grada, Wong, La Vecchia, Tam, Cooper and Naghavi. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2021 Damiani, Bragazzi, Karimkhani Aksut, Wu, Alicandro, McGonagle, Guo, Dellavalle, Grada, Wong, La Vecchia, Tam, Cooper and Naghavi. 2021 Damiani, Bragazzi, Karimkhani Aksut, Wu, Alicandro, McGonagle, Guo, Dellavalle, Grada, Wong, La Vecchia, Tam, Cooper and Naghavi |
| Copyright_xml | – notice: Copyright © 2021 Damiani, Bragazzi, Karimkhani Aksut, Wu, Alicandro, McGonagle, Guo, Dellavalle, Grada, Wong, La Vecchia, Tam, Cooper and Naghavi. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2021 Damiani, Bragazzi, Karimkhani Aksut, Wu, Alicandro, McGonagle, Guo, Dellavalle, Grada, Wong, La Vecchia, Tam, Cooper and Naghavi. 2021 Damiani, Bragazzi, Karimkhani Aksut, Wu, Alicandro, McGonagle, Guo, Dellavalle, Grada, Wong, La Vecchia, Tam, Cooper and Naghavi |
| DBID | AAYXX CITATION NPM 3V. 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.3389/fmed.2021.743180 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Database Suite (ProQuest) ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2296-858X |
| ExternalDocumentID | oai_doaj_org_article_e30326d85f6f4c018d2559d79fbca9d3 PMC8716585 34977058 10_3389_fmed_2021_743180 |
| Genre | Journal Article |
| GeographicLocations | Poland United States--US Norway Taiwan Russia |
| GeographicLocations_xml | – name: Taiwan – name: Russia – name: Poland – name: United States--US – name: Norway |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM ACXDI IAO IEA IHR IHW IPNFZ ISR NPM RIG 3V. 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA K9. M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c556t-75ae8ab8388dbe0e9755092c2048476aa09bf80b8c59374290e3d44aa8ffd74c3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 255 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000738792900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2296-858X |
| IngestDate | Fri Oct 03 12:51:14 EDT 2025 Tue Sep 30 16:50:02 EDT 2025 Fri Sep 05 07:24:53 EDT 2025 Thu Nov 20 00:21:37 EST 2025 Thu Jan 02 22:57:28 EST 2025 Sat Nov 29 06:16:29 EST 2025 Tue Nov 18 22:33:34 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | global health epidemiology prevalence incidence psoriasis years lived with disability (YLDs) |
| Language | English |
| License | Copyright © 2021 Damiani, Bragazzi, Karimkhani Aksut, Wu, Alicandro, McGonagle, Guo, Dellavalle, Grada, Wong, La Vecchia, Tam, Cooper and Naghavi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c556t-75ae8ab8388dbe0e9755092c2048476aa09bf80b8c59374290e3d44aa8ffd74c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Edited by: Robert Gniadecki, University of Alberta, Canada Reviewed by: Minxue Shen, Central South University, China; Rosa Parisi, University of Mancester, United Kingdom This article was submitted to Dermatology, a section of the journal Frontiers in Medicine |
| OpenAccessLink | https://doaj.org/article/e30326d85f6f4c018d2559d79fbca9d3 |
| PMID | 34977058 |
| PQID | 3272679900 |
| PQPubID | 7426803 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e30326d85f6f4c018d2559d79fbca9d3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8716585 proquest_miscellaneous_2616290664 proquest_journals_3272679900 pubmed_primary_34977058 crossref_primary_10_3389_fmed_2021_743180 crossref_citationtrail_10_3389_fmed_2021_743180 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-16 |
| PublicationDateYYYYMMDD | 2021-12-16 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Lausanne |
| PublicationTitle | Frontiers in medicine |
| PublicationTitleAlternate | Front Med (Lausanne) |
| PublicationYear | 2021 |
| Publisher | Frontiers Media SA Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media SA – name: Frontiers Media S.A |
| References | Yeung (B36) 2013; 149 Peng (B32) 2021; 3 Lande (B11) 2014; 5 B27 Xu (B33) 2021; 62 Smith (B38) 2009; 161 Karimkhani (B23) 2017; 23 McGonagle (B2) 2019; 15 Dhana (B35) 2019; 80 (B16) 2020; 396 GBD (B37) 2018; 392 Murray (B18) 2012; 380 Picard (B26) 2018; 38 Pietrzak (B12) 2019; 15 Henes (B8) 2014; 34 Murray (B19) 2012; 380 (B17) 2018; 392 Schett (B3) 2017; 13 Strober (B15) 2018; 78 GBD (B24) 2016; 388 AlQassimi (B29) 2020; 59 Yuan (B10) 2019; 71 Koo (B13) 2017; 31 Kaufman (B28) 2018; 19 B39 Haroon (B9) 2013; 72 GBD 2016 DALYs HALE (B21) 2017; 390 Greb (B1) 2016; 2 Parisi (B31) 2020; 369 Haneke (B4) 2017; 7 Gonzalez (B14) 2016; 232 GBD 2013 DALYs HALE (B20) 2015; 386 Feldman (B40) 2005 Sewerin (B6) 2019; 78 Husni (B34) 2017; 47 Egeberg (B7) 2019; 9 (B22) 2018 Parisi (B5) 2013; 133 Mehrmal (B30) 2021; 84 Stevens (B25) 2016; 388 B41 |
| References_xml | – volume: 369 start-page: m1590 year: 2020 ident: B31 article-title: National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study publication-title: BMJ doi: 10.1136/bmj.m1590 – volume: 34 start-page: 227 year: 2014 ident: B8 article-title: High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study publication-title: Rheumatol Int. doi: 10.1007/s00296-013-2876-z – start-page: ii65 volume-title: Ann Rheum Dis. year: 2005 ident: B40 article-title: Psoriasis assessment tools in clinical trials – volume: 38 start-page: 96 year: 2018 ident: B26 article-title: International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity publication-title: J Clin Immunol. doi: 10.1007/s10875-017-0464-9 – volume: 388 start-page: e19 year: 2016 ident: B25 article-title: Guidelines for accurate and transparent health estimates reporting: the GATHER statement publication-title: Lancet. doi: 10.1016/S0140-6736(16)30388-9 – volume: 13 start-page: 731 year: 2017 ident: B3 article-title: Enthesitis: from pathophysiology to treatment publication-title: Nat Rev Rheumatol. doi: 10.1038/nrrheum.2017.188 – volume: 380 start-page: 2197 year: 2012 ident: B19 article-title: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010 publication-title: Lancet. doi: 10.1016/S0140-6736(12)61690-0 – volume: 15 start-page: 369 year: 2019 ident: B12 article-title: Serum lipid metabolism in psoriasis and psoriatic arthritis - an update publication-title: Arch Med Sci. doi: 10.5114/aoms.2018.74021 – volume: 232 start-page: 541 year: 2016 ident: B14 article-title: Systematic review of health-related quality of life in adolescents with psoriasis publication-title: Dermatology. doi: 10.1159/000450826 – volume: 2 start-page: 16082 year: 2016 ident: B1 article-title: Psoriasis publication-title: Nat Rev Dis Primers. doi: 10.1038/nrdp.2016.82 – ident: B41 – volume: 15 start-page: 113 year: 2019 ident: B2 article-title: Pathophysiology, assessment and treatment of psoriatic dactylitis publication-title: Nat Rev Rheumatol. doi: 10.1038/s41584-018-0147-9 – volume: 23 start-page: 406 year: 2017 ident: B23 article-title: Global skin disease morbidity and mortality: an update from the global burden of disease study 2013 publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2016.5538 – volume: 7 start-page: 51 year: 2017 ident: B4 article-title: Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management publication-title: Psoriasis. doi: 10.2147/PTT.S126281 – ident: B27 – volume: 390 start-page: 1260 year: 2017 ident: B21 article-title: Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016 publication-title: Lancet. doi: 10.1016/S0140-6736(17)32130-X – volume: 396 start-page: 1204 year: 2020 ident: B16 article-title: Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019 publication-title: Lancet. doi: 10.1016/S0140-6736(20)30925-9 – volume: 84 start-page: 46 year: 2021 ident: B30 article-title: The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the global burden of disease study 2017 publication-title: J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.139 – volume: 47 start-page: 351 year: 2017 ident: B34 article-title: The psychosocial burden of psoriatic arthritis publication-title: Semin Arthritis Rheum. doi: 10.1016/j.semarthrit.2017.05.010 – volume: 380 start-page: 2063 year: 2012 ident: B18 article-title: GBD 2010: design, definitions, and metrics publication-title: Lancet. doi: 10.1016/S0140-6736(12)61899-6 – volume: 31 start-page: 1999 year: 2017 ident: B13 article-title: Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression publication-title: J Eur Acad Dermatol Venereol. doi: 10.1111/jdv.14460 – volume: 392 start-page: 1789 year: 2018 ident: B17 article-title: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017 publication-title: Lancet doi: 10.1016/S0140-6736(18)32279-7 – volume-title: Global Burden of Disease Study 2017 (GBD 2017) Disability Weights year: 2018 ident: B22 – ident: B39 – volume: 59 start-page: 566 year: 2020 ident: B29 article-title: Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017 publication-title: Int J Dermatol. doi: 10.1111/ijd.14864 – volume: 80 start-page: 1332 year: 2019 ident: B35 article-title: All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis publication-title: J Am Acad Dermatol. doi: 10.1016/j.jaad.2018.12.037 – volume: 133 start-page: 377 year: 2013 ident: B5 article-title: Identification and management of psoriasis and associated comorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence publication-title: J Invest Dermatol. doi: 10.1038/jid.2012.339 – volume: 78 start-page: 286 year: 2019 ident: B6 article-title: Prevalence and incidence of psoriasis and psoriatic arthritis publication-title: Ann Rheum Dis. doi: 10.1136/annrheumdis-2018-214065 – volume: 5 start-page: 5621 year: 2014 ident: B11 article-title: The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis publication-title: Nat Commun. doi: 10.1038/ncomms6621 – volume: 71 start-page: 941 year: 2019 ident: B10 article-title: Identification of novel autoantibodies associated with psoriatic arthritis publication-title: Art Rheumatol. doi: 10.1002/art.40830 – volume: 392 start-page: 2091 year: 2018 ident: B37 article-title: Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related sustainable development goals for 195 countries and territories: a systematic analysis for the global burden of disease study 2017 publication-title: Lancet doi: 10.1016/S0140-6736(18)32281-5 – volume: 78 start-page: 323 year: 2018 ident: B15 article-title: Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the corrona psoriasis registry publication-title: J Am Acad Dermatol. doi: 10.1016/j.jaad.2017.10.012 – volume: 19 start-page: 405 year: 2018 ident: B28 article-title: Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial/ethnic groups publication-title: Am J Clin Dermatol. doi: 10.1007/s40257-017-0332-7 – volume: 149 start-page: 1173 year: 2013 ident: B36 article-title: Psoriasis severity and the prevalence of major medical comorbidity: a population-based study publication-title: JAMA Dermatol. doi: 10.1001/jamadermatol.2013.5015 – volume: 386 start-page: 2145 year: 2015 ident: B20 article-title: Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition publication-title: Lancet. doi: 10.1016/S0140-6736(15)61340-X – volume: 62 start-page: e554 year: 2021 ident: B33 article-title: Demographic and epidemiological drivers of global burden of psoriasis publication-title: Australas J Dermatol. doi: 10.1111/ajd.13710 – volume: 72 start-page: 736 year: 2013 ident: B9 article-title: High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimalperformance of screening questionnaires publication-title: Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-201706 – volume: 161 start-page: 987 year: 2009 ident: B38 article-title: British association of dermatologists' guidelines for biologic interventions for psoriasis 2009 publication-title: Br J Dermatol. doi: 10.1111/j.1365-2133.2009.09505.x – volume: 388 start-page: 1813 year: 2016 ident: B24 article-title: Measuring the health-related sustainable development goals in 188 countries: a baseline analysis from the global burden of disease study 2015 publication-title: Lancet doi: 10.1016/S0140-6736(16)31467-2 – volume: 3 start-page: 472 year: 2021 ident: B32 article-title: Burden of skin disease - China, 1990-2019 publication-title: China CDC Wkly. doi: 10.46234/ccdcw2021.123 – volume: 9 start-page: e028116 year: 2019 ident: B7 article-title: Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort publication-title: BMJ Open. doi: 10.1136/bmjopen-2018-028116 |
| SSID | ssj0001325413 |
| Score | 2.6079423 |
| Snippet | Background:
Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted... Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted therapies have... Background: Psoriasis is a common, chronic, inflammatory, debilitating, systemic disease with a great impact on healthcare systems worldwide. As targeted... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 743180 |
| SubjectTerms | Age groups Disease Epidemiology Estimates global health incidence Medicine Population prevalence Primary care Psoriasis Psoriatic arthritis Regions Rheumatoid arthritis Trends Violations years lived with disability (YLDs) |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIMSF9yNQkJG4IDU0iZ3Y5oJ4rUCCqkKA9mY5fpSVlqSss0j8e2aSbLqLUC9cEydx8tme-TyTbwh5KngogOSI1FvHUs44T-uCi9Tmrlahkr7qlZi-fRRHR3I-V8fjhlsc0yo3a2K_ULvW4h75IdyvqASsndnL058pVo3C6OpYQuMiuYRls3Gci7k422NhQH9yNkQngYspAMujPGiRP0fLiVqQW9aoF-3_l6f5d8LklgWaXf_fvt8g10bfk74aBstNcsE3t8iVT2N0_TbBInZ0KAJwQD_7k36X8ICaxtFRPntJh98eaBvocYRHmLiIL6BtXC-72Lf80ETk-5HOVu0P2k133Lry7RAUouAVKIqJjL_vkK-zd1_evE_H0gypLcuqS0VpvDS1ZFK62mdeCWA6qrAoA8xFZUym6iCzWtoS_B-weZlnjnNjZAhOcMvukr2mbfx9QsG_sAGlnxRQQXCHVI2JOqVRLC-t5DwhhxuItB11y7F8xlIDf0FQNYKqEVQ9gJqQZ9MVp4NmxzltXyPqUztU2-4PtKsTPU5e7cHOF5WTZagCt1kuHRIxJ1SorVGOJWR_g7sel4Coz0BPyJPpNExejMiYxrfrqIG-Vqi3X8Fb3huG2NQTxsE1z0qZELEz-Ha6unumWXzvBcKRBAMNfHB-tx6Sq_ghMDcnr_bJXrda-0fksv3VLeLqcT-T_gDpiiV2 priority: 102 providerName: ProQuest |
| Title | The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34977058 https://www.proquest.com/docview/3272679900 https://www.proquest.com/docview/2616290664 https://pubmed.ncbi.nlm.nih.gov/PMC8716585 https://doaj.org/article/e30326d85f6f4c018d2559d79fbca9d3 |
| Volume | 8 |
| WOSCitedRecordID | wos000738792900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: 8C1 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: PIMPY dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagIMSl4lm2lJWRuCA1NA_HD260dEUlulpVgJZT5PgBKy0JWmeR-PfMJGmURQguXCwlthPbM87MZ08-E_JCMJ8CyBGRMzaLWMZYVKZMRCaxpfJcOt4yMX16L-ZzuVyqxeioL4wJ6-iBu4E7cfCNTbmVueeemTiRFp1gK5QvjVa25fmMhRqBqXZ1JQPgk2TdviSgMAVickgMmiav0GYiC-TIDrV0_X_yMX8PlRzZntk9st87jfRN19j75IarHpA7l_22-EOCp8_Rjr3_mF65L-3y3jHVlaU97_Wadv8r0NrTRahB68IqvIayYbtuQlvyogoI1AOdbepvtBmeOKr5ttvNoWDOFcUIxJ-PyMfZ-Yezd1F_pkJk8pw3kci1k7qUmZS2dLFTAiCKSg3y9zLBtY5V6WVcSpOD4wLGKnaZZUxr6b0VzGSPyV5VV-4JoeAYGI-cTQowHPgxqsQIm1yrLMmNZGxCTq5HuDA94Tiee7EuAHigTAqUSYEyKTqZTMjLocb3jmzjL2VPUWhDOaTJbm-A8hS98hT_Up4JOboWedHP3VCA5qZcgJWGdzwfsmHW4VaKrly9DQXgTo5E-Rx6edBpyNCSjIFPHedyQsSO7uw0dTenWn1tmb0RvQJ-O_wffXtK7uJwYehNwo_IXrPZumfktvnRrMJmSm6KpWhTCak8S6bk1un5fHE1bScSXC0uLheffwFyXB2K |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGh4AX7pfAACPBA9LCcnFiGwkhYFSr1lYV2tB4MontjEolGXUL2p_iN3JOknYtQnvbA6_xRXby-fh89sl3CHnOWREByeG-1Sb2WcyYn0eM-zo0uSxSYdNaielznw-H4uhIjjbI78W_MBhWubCJtaE2lcYz8h3oL0o52M7g7ckPH7NG4e3qIoVGA4t9e_oLKJt709uF7_siirofDz7s-W1WAV8nSTrzeZJZkeUiFsLkNrCSg5MuI40KtoynWRbIvBBBLnQCWzeY68DGhrEsE0VhONMx9HuJbDIEe4dsjnqD0ZezU50YCFcYN_ehwP4kwMOiIGkUvsK9GtUnV_a_Ok3Av3zbv0M0V_a87o3_7W3dJNdb75q-a5bDLbJhy9vkyqCNH7hDME0fbdIcbNNP9rg-B92mWWloKxA-oc2PHbQq6MjBlDI3dq-hrptPZq6u2Ssdnmg42p1W3-ls2eNKy93m2ouC3yMphmqe3iWHFzLxe6RTVqV9QCh4ULpAcSsJZBccPpljKFKSyThMtGDMIzsLSCjdKrNjgpCJAoaGIFIIIoUgUg2IPPJy2eKkUSU5p-57RNmyHuqJ1w-q6bFqzZOy4MlEqRFJkRZMB6EwSDUNl0WuM2lij2wtcKZaI-fUGcg88mxZDOYJ75yy0lZzp4Cgp5hRIIVZ3m8gvRxJzIB8BInwCF8D-9pQ10vK8bdaAh1pPhDdh-cP6ym5uncw6Kt-b7j_iFzDl4KRSGG6RTqz6dw-Jpf1z9nYTZ-065iSrxe9GP4ARqaDYg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Global%2C+Regional%2C+and+National+Burden+of+Psoriasis%3A+Results+and+Insights+From+the+Global+Burden+of+Disease+2019+Study&rft.jtitle=Frontiers+in+medicine&rft.au=Damiani%2C+Giovanni&rft.au=Bragazzi%2C+Nicola+Luigi&rft.au=Karimkhani+Aksut%2C+Chante&rft.au=Wu%2C+Dongze&rft.date=2021-12-16&rft.issn=2296-858X&rft.eissn=2296-858X&rft.volume=8&rft_id=info:doi/10.3389%2Ffmed.2021.743180&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fmed_2021_743180 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon |